A research study at the NIH is testing whether a GLP-1 investigational medication called Tirzepatide can help people with Alcohol Use Disorder (AUD) and Metabolic Alcohol-Associated Liver Disease (MetALD) to reduce alcohol intake.
You May Be Eligible If You Are:
• Adults ages 21+
• Drink alcohol regularly
• Overweight; BMI between 25-40
During This Study You Will:
• Have screening and health assessments
• Visit weekly for 12 weeks
• Take study medication or placebo administered via injection
• Have liver and brain scans (optional)
• Provide samples to help researchers study genetics linked to alcohol use and liver disease
The NIH Clinical Center Research hospital located in Bethesda, MD. Metro red line (Medical Center stop).
For more information:
Phone: show contact info
https://www.cc.nih.gov/recruit